Cyclooxygenase-2 inhibitors in cancer prevention and treatment

Advances in Experimental Medicine and Biology

Volumn 532, Issue , 2003, Pages 209-213

  Masferrer, Jaime L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE; FLUOROURACIL; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; NITROGEN OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PROSTAGLANDIN; SYNTHETASE; TUMOR PROMOTER; VASCULOTROPIN;

ADENOMATOUS POLYP; ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLADDER CANCER; BLOOD VESSEL; BREAST CANCER; CANCER; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVITY; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LUNG CANCER; LUNG METASTASIS; METASTASIS; PANCREAS CANCER; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; SIDE EFFECT; SKIN CANCER; SMOOTH MUSCLE; SOLID TUMOR; STOMACH CANCER; TUMOR CELL; UPREGULATION;

EID: 0141571151     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0081-0_16     Document Type: Conference Paper

References (58)

1. Gridley, G., McLaughlin, J.K., Ekbon, A, et al.: Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst. (1993) 85:307-311.
2. Sandler, RS: Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Lippincott-Raven Publishers (1996) Philadelphia, PA.
3. Suh, O, Mettlin, C, Petrelli, NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer (1993) 72:1171-1177.
4. Marneit, LJ: Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Preventive Med. (1995) 24:103-106.
5. Reeves, MJ, Newcomb, PA, Trentham-Dietz, A, Storer, BE, Remington, PL: Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol. Biomark. Prev. (1996) 5:955-960.
6. Rosenberg, L, Palmer, JR, Zauber, GA, Warshauer, ME, Stolley, PD, Shapiro, S: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J. Natl. Cancer Inst. (1991) 83:355-358
7. Peleg, II, Maibach, HT, Brown, SH, Wilcox, CM: Aspirin andnonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. (1994) 121:394-399.
8. Muscat, JE, Stellman, SD, Wynder, EL: Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer (1994) 74:1847-1854.
9. Morgan, G: Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut (1996) 38:646-648.
10. Thun, MJ, Namboodiri, MM, Calle, EE, Flanders, WD, Heath, CW JR: Aspirin use and risk of fatal cancer. Cancer Res. (1993) 53:1322-1327.
11. Schreinemachers, DM, Everson, RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology (1994) 5:138-146.
12. Thun, MJ: NSAID use and decreased risk of gastrointestinal cancers. Gastroenterology Clinics of North America (1996) 25:333-348.
13. Farrow, DC, Vaughan, TL, Hansten, PD, et al.: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epid. Biom. & Prev. (1998) 7:97-102.
14. Funkhouser, EM, Sharp, GB: Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 76:1116-1119.
15. Giovannucci, E, Egan, KM, Hunter, DJ et al.: Aspirin and the risk of colorectal cancer in women. N. Eng. J. Med. (1995) 333:609-614.
16. Rigas, B, Goldman Giovannucci, E, Rimm, EB, Stampfer, MJ, Coldtiz, GA; Ascherio, A, Willett, W C: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. (1994) 121:241-246.
17. Bennett, A, Berstock, DA, Raja, B, Stanford, IF: Survival time after surgery is inversely related to amounts of prostaglandin extracted from human breast cancer. Br. J. Pharmacol. (1979) 66:451P.
18. 2. Gut (1994) 35:675-678.
19. Rigas, B, Goldman, IS, Levine, L: Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. (1993) 122:518-523.
20. Yang, VW, Shields, JM, Hamilton, SR et al.: Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. (1998) 58:1750-1753.
21. Oshima M, Dinchuk JE, Kargman SL et al.: Suppression of intestinal polyposis in APC-delta-716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 87:803-809.
22. Labayle, D., Fisher, D., Vieln, P et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 101:635-639.
23. Yoshimi, N, Kawabata, K, Hara, A: Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res. (1997) 88:1044-1051.
24. Reddy BS, Rao, CV, Seibert, K: Evaluation of cyclooxygenase-2 inhibito for potential chemopreventive properties in colon carcinogenesis. Cancer Res. (1996) 56:4566-4569.
25. Kawamori, T, Rao, CV, Seibert, K, Reddy, BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. (1998) 58:409-412.
26. Wilson, KT, FU, S, Ramanujam, KS, Meltzer, SJ: Increased expression of inducible nitric oxide and cyclooxygenase -2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. (1998) 58:2929-2934.
27. Soslow, RA, Dannenberg, AJ, Rush, D, et al.: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer (2000) in review.
28. Eeberhart, CE, Coffey, RJ, Radhika, A, et al.: Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 107:1183-1188.
29. Hida, T, Tayabe, Y, Achiwa, H, et al.: Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. (1998) 58:3761-3764.
30. Mohammed, SI, Knapp, DW, Bostwick, DG: Expression of cyclooxygenase-2 in human invasive transitional cell carcinoma of the urinary bladder. Cancer Research Adv. In Brief (1999) 59:5647-5650.
31. Buckman, SY, Gresham, A, Hale, P, et al.: COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis (1998) 19(5):723-729.
32. Koki, AT, Leahy, KM, Masferrer, JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp. Opin. Invest. Drugs (1999) 8(10):1623-1638.
33. Seed, MP:. Angiogenesis inhibition as a drug target for disease: an update Exp. Opin. Invest. Drugs. (1996) 5(12):1617-1637.
34. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med. (1983) 172(2):214-218.
35. Rolland, PH, Martin, PM, Jacquemeier, J, Rolland, AM, Togs, M: Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Institute (1980) 64:1061-1070.
36. Karmali, RA, Welts, S, Thaler, HT, Lefevre, F: Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br. J. Cancer (1983) 48:689-696.
37. Fulton, AM, Ownby, HE, Frederick, J, Brennan, MJ: Relationship of tumor prostaglandin levels to early recurrence in women with primary breast cancer: a clinical update. Invasion Metastasis (1986) 6:83-94.
38. Bennett, A, Berstock, DA, Raja, B, Stanford, IF: Survival time after surgery is inversely related to amounts of prostaglandin extracted from human breast cancer. Br. J. Pharmacol. (1979) 66:451P.
39. Sheehan
40. Chan G, Boyle JO, Yang EK et al.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. (1999) 59:991-994.
41. Tucker ON, Dannenberg AJ, Yang EK et al.: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. (1999) 59:987-990.
42. Gupta, S, Srivastava, M, Ahmad, N, Bostwick, DG, Mukhtar, H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42:73-78.
43. Hwang, D, Scollard, D, Byrene, J, Levine, E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Insti. (1998) 90:455-460.
44. Parrett, ML, Harris, RE, Joarder, FS, Ross, MS, Clausen, KP, Robertson, FM: Cyclooxygenase-2 gene expression in human breast cancer. Int. J. of Oncol. (1997) 10:503-507.
45. Wolff, H, Saukkonen, KL, Anttila, S, Karjalainen, A, Vainio, H, RISTIMAKI, A: Expression of cyclooxygenctse-2 in human lung carcinoma. Cancer Res. (1998) 58:4997-5001.
46. Toyoaki, H, Yatabe, Y, Achiva, H, et al.: Increased cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. (1998) 58:3761-3764.
47. Zimmerman, KC, Sarbia, M, Weber, A, Borchard, F, Gabbert, H, Schror, K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. (1999) 59:198-204.
48. Knapp, DW, Glickman, NW, Denicola, DB, Bonney, PL, Lin, TL, Glickman, LT: Naturally-occurring canine transitional cell carcinoma of the urinary bladder, a relevant model of human invasive bladder cancer. Urologic Oncology (1999) (in press).
49. Mohammed, S., Lafayette, W, Foster, R et al.: Expression of cyclooxygenase COX-1 and COX-2 in human invasive transitional cell carcinoma of the urinary bladder. American Urological Association Meeting, Dallas, TX (1999)
50. Lundholm, K, Gelin, J, Hyltander, A, Lonnroth, C, Sandstrom, R, Svaniger, G: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res., (1994) 5:5602-5606.
51. Masferrer, JL, Leahy, K, Koki, AT, Zweifel, BS, Settle, SL, Woerner, BM, Edwards, DA, Flickinger, AG, Moore, RJ, Seiebert, K: Angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. (2000) Cancer Res. 60(5):1306-1311.
52. Tsuji, M, Dubois, RN: Alterations in cellular adehision and apoptosis in epithelial-cells overexpressing prostaglandin-endoperoxide synthase-2. Cell (1995) 83:493-501.
53. Milas, L, Kishi, K, Hunter, N, Masferrer, JL, Tofilon, PJ: Enhancement of tumor response to g-irradiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. (1999) 91:1501-1504.
54. Kishi, K, Petersen, S, Petersen, C, Hunter, N, Masferrer, JL, Tofilon, PJ, Milas, L: Preferential enhancement of tumor radioresponse by a COX-2 inhibitor. Cancer Res. (2000) 60:1326-1331.
55. Tsuji, M, Kawano, S, Tsuji, S, Sawahoka, H, Hori, M, Duboise, RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. (1998) Cell 93:705-716.
56. Sheng, H, Williams, CS, Shao, J, Liang, P, Duboise, RN, Beauchamp, RD: Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-I fibroblasts and the role of mitogen-activated protein kinase pathway. (1998) J. Biol. Chem. 273:22120-22127.
57. Tsuji, M, Kawano, S, Duboise, RN: Cyclooxgynase-2 expression in human colon cancer cells increases metastatic potential. (1997) Proc. Natl. Acad Sci. USA 94:3336-3340.
58. Huang, M, Stolina, M, Sharma, S, Mao, JT, Zhu, L, Miller, PW, Wollman, J, Herschman, H, Dubinett, SM: Non-small cell lung cancer cyclooxygenase-2 dependent regulation of interleukin-10 and down-regulation of interleukin-12 production. (1998) Cancer Res. 58:1208-1216.